Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

International Rare And Severe Psoriasis Expert Network (IRASPEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04359394
Recruitment Status : Not yet recruiting
First Posted : April 24, 2020
Last Update Posted : January 27, 2021
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.

Condition or disease Intervention/treatment
Pustular Psoriasis (PP) Other: biological sampling Other: Phenotypic description Other: Photography

Detailed Description:
This project is to describe the natural course of disease in different subtypes of PP. The network builds on a static registry that was based on a one-time clinical characterization of PP patients in Europe (ERASPEN). The International Rare and Severe Psoriasis Expert Network (IRASPEN) already has multiple clinicians involved who have successfully characterized and included their patients in ERASPEN. IRASPEN addresses the question of temporal evolution of clinical features and is actually a non-interventional prospective registry that aims to describe the clinical course and responses to already established treatments of a large number of PP patients over a period of 5 years. The data collection with this registry will give insight on the natural course of PP disease revealing the burden of disease including frequency and severity of flares and the role of therapeutic interventions.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 180 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: International Rare And Severe Psoriasis Expert Network (IRASPEN) - A Prospective Registry With Genotype-Phenotype Correlation
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : December 2030
Estimated Study Completion Date : December 2030


Group/Cohort Intervention/treatment
PP patients
patients with active PP
Other: biological sampling
In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.

Other: Phenotypic description
Phenotypic characterization of the patient's clinical features

Other: Photography
All affected areas will be photographed at each visit with 2-dimensional standardized photography




Primary Outcome Measures :
  1. Change in Physician Global Assessment (PGA) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    modified PGA (physician's assessment of psoriatic lesions) scoring the erythema, pustules, and scaling of all GPP or PPP lesions from 0 to 4. Each component is graded separately, the average is calculated, and the final PGA is determined from this composite score. A lower score indicates a lesser severity, with 0 being clear and 1 being almost clear.


Secondary Outcome Measures :
  1. Change in Generalized Pustular Psoriasis (GPP) Area and Severity Index (GPPASI) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    Measure of severity and area of psoriatic lesions in patients with psoriasis. It is a tool that provides a numeric scoring for a patient's overall GPP disease state,ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected by erythema, pustules and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions.

  2. Change in Dermatology Life Quality Index (DLQI) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The Dermatology Life Quality Index (DLQI) consists of 10 questions concerning patient's perception of the impact of skin diseases on different aspects of their health related QoL over the last week. The DLQI evaluates the impact of the patient's skin disease on daily activities, leisure, work and personal relationships. Each question is scored on a 4-point Likert scale.

  3. Change in EuroQol (EQ-5D) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The EuroQol is a generic questionnaire. It is a preference based health status and multi attribute utility scale that produces a single index score for each state of health. These score ranges from 0 to 1, where 1 is equivalent to full health and 0 equivalent to death

  4. Change in Work Productivity and Activity Impairment Questionnaire-General Health (WPAI-GH) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The Work Productivity and Activity Impairment Questionnaire-General Health (WPAI-GH) consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS)[

  5. Change in psoriasis symptom scale (PSS) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The psoriasis symptom scale (PSS) is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to assess how unpredictable, uncontrollable, and overloaded respondents find their lives to be. The scale also includes a number of direct queries about current levels of experienced stress. Moreover, the questions are of a general nature and hence are relatively free of content specific to any sub-population group. The questions in the PSS ask about feelings and thoughts during the last month.

  6. Change in Disease activity Visual analogue Scale (VAS) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The disease VAS is a unidimensional measure of disease intensity. The VAS is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not given. The disease intensity VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their current disease intensity.

  7. Change in Pain Visual analogue Scale (VAS) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The pain VAS is a unidimensional measure of pain intensity, which has been widely used in diverse adult populations. The pain VAS is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not given. The pain VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity.

  8. Number of flares in the last 2 years [ Time Frame: at Baseline ]
    Number of flares in the last 2 years

  9. Number of flares since the last visit [ Time Frame: At week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    Number of flares since the last visit

  10. Change in Palmoplantar Pustulosis (PPP) Area and Severity Index (PPPASI) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    investigator assessment of the extent and severity of pustular and plaque lesions on the palms and soles presenting in PPP patients. This tool provides a numeric scoring for patients overall PPP disease state, ranging from 0 to 72. It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation).

  11. Change in Psoriasis Area and Severity Index (PASI) [ Time Frame: At Baseline, week 12, week 24, week 36, week 52, week 64, Week 76, week 104, week 130, week 156, week 182, week 208, week 234, week 260 ]
    The Psoriasis Area and Severity Index (PASI) is a composite variable used to assess the severity of Psoriasis. The PASI evaluates the area of psoriatic involvement in 4 main areas (head, trunk, upper and lower extremities) and the severity of the psoriatic lesions with respect to three target symptoms: erythema, infiltration and desquamation (actual percentages of area involvement) .


Biospecimen Retention:   Samples With DNA
fresh blood (whole blood) and skin biopsies (formalin-fixation followed by embedding in paraffin and fixation in RNAlater) for isolation of RNA, DNA


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The project population encompasses all patients aged 6 months and over with active PP in the participating countries. Patients will be recruited by consecutive ongoing recruitment in the investigators' clinical practice during 5 years.
Criteria

Inclusion Criteria:

  • Written informed consent of the patient or legal proxy in the registry
  • Diagnosis of PP confirmed by a dermatologist in the participant. The type of PP can be any one of PPP, GPP/Acute Generalized Exanthematous Pustulosis (AGEP), ACH or a mixed phenotype, according to the judgment of the investigator
  • GPP: Primary, sterile, macroscopically visible epidermal pustules on non-acral Skin with or without systemic Inflammation; with or without plaque Psoriasis; either relapsing (>1 episode) or persistent (>3 months)
  • PPP: Primary, persistent (>3 months), sterile, macroscopically visible epidermal pustules on palms and/or soles with or without plaque psoriasis
  • ACH: Primary, persistent (>3 months), sterile, macroscopically visible epidermal pustules affecting the nail apparatus with or without plaque psoriasis
  • At the timepoint of inclusion, the participant must have active pustulation with either white, yellow or brown pustules
  • Sufficient language skills (in the languages which the patient information and the consent form is available) for the informed consent to participate
  • Patients of all ancestries and skin pigment type can be included
  • Direct non-affected adult (>18 years old) relatives of the participant (up to two, namely mother, father, sibling) with the purpose to provide DNA for family trio sequencing analysis

Exclusion Criteria:

  • Any medical or psychological condition in the treating physician's opinion which may prevent the patient in registry participation for the next 5 years
  • Lack of informed consent for registry participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04359394


Contacts
Layout table for location contacts
Contact: Alexander Navarini, Prof. Dr. med. Dr. sc. nat. +41 61 328 60 80 alexander.navarini@usb.ch

Locations
Layout table for location information
Switzerland
Dermatology, University Hospital Basel
Basel, Switzerland, 4031
Contact: Alexander Navarini, Prof. Dr. med. Dr. sc. nat.    +41 61 328 60 80    alexander.navarini@usb.ch   
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Boehringer Ingelheim
Investigators
Layout table for investigator information
Principal Investigator: Alexander Navarini, Prof. Dr. med. Dr. sc. nat. Dermatologie, Universitätsspital Basel
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT04359394    
Other Study ID Numbers: 2020-00425; sp18Navarini2
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: January 27, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Basel, Switzerland:
Palmoplantar Psoriasis (PPP)
IRASPEN International Rare and Severe Psoriasis Expert Network
ERASPEN European Rare and Severe Psoriasis Expert Network
Psoriasis
Generalized pustular psoriasis (GPP)
Acrodermatitis continua of Hallopeau (ACH)
Interleukin 36 Receptor Antagonist Gene (IL36RN)
Caspase Recruitment Domain-containing protein 14 (CARD14)
Adaptor Related Protein Complex 1 Subunit Sigma 3 (AP1S3)
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases